The verdict
Our read at a glance.
Whether etelcalcetide's approved benefit is understood as lowering parathyroid hormone in adults on hemodialysis with secondary hyperparathyroidism, while whether that lowering improves bone, heart, or survival outcomes remains debated for the calcimimetic class.
- The signal
- Randomized trials show etelcalcetide lowers parathyroid hormone in dialysis patients with secondary hyperparathyroidism, and in a head-to-head trial it lowered PTH at least as well as the older oral calcimimetic cinacalcet.
- The unknown
- Whether lowering parathyroid hormone with calcimimetics actually improves harder outcomes like fractures, heart disease, or survival is still debated, since the major outcomes trial of the oral calcimimetic in this class did not clearly show that benefit.
- Our read
- A convenient, effective way to lower parathyroid hormone in dialysis patients, given at the dialysis chair instead of as a daily pill. It clearly does its biochemical job, but whether driving parathyroid hormone down translates into fewer fractures or longer life is the unsettled question for the whole calcimimetic class. Blood calcium has to be watched.
The mechanism
How it works.
Parathyroid glands sit in the neck and release parathyroid hormone (PTH), which raises blood calcium. They sense calcium through a 'calcium-sensing receptor' and dial PTH down when calcium is high. In long-term kidney failure this control breaks down and the glands pump out too much PTH. Etelcalcetide is a small synthetic peptide that latches onto the calcium-sensing receptor and makes it more sensitive, so the gland behaves as if calcium is higher than it is and releases less PTH. It is given into the bloodstream at the end of each dialysis session, which is why people do not have to remember a daily pill. Because it lowers PTH, it can also pull blood calcium down, which has to be watched.
Safety & regulatory boundary
The consequential part.
The main risk is low blood calcium, which can cause heart-rhythm changes or seizures, so calcium is monitored; worsening heart failure and stomach or intestinal bleeding are also noted. Etelcalcetide is given intravenously at the end of hemodialysis and is approved only for secondary hyperparathyroidism in adults on hemodialysis, not for earlier kidney disease or primary hyperparathyroidism. Parsabiv is a prescription drug used under nephrology care.
What's next
What we're watching.
Whether calcimimetics improve fractures, cardiovascular events, or survival; long-term bone effects from over-suppressing parathyroid hormone; and how it is positioned against oral cinacalcet.
Context
Why this is discussed.
People on long-term dialysis often develop overactive parathyroid glands, which throws off calcium and phosphate and harms bones and blood vessels. Etelcalcetide is given right at dialysis to bring the overactive parathyroid signal back down, which is easier to keep up with than a daily pill.
The evidence base
18 cited references.
Regulatory & labels1
Amgen, Inc (FDA label) · 2026
Registered trials6
ClinicalTrials.gov · PHASE3 · RECRUITING · 2019-12-20
ClinicalTrials.gov · PHASE3 · RECRUITING · 2019-04-29
ClinicalTrials.gov · NOT_YET_RECRUITING · 2024-05-01
ClinicalTrials.gov · PHASE2 · COMPLETED · 2018-09-06
ClinicalTrials.gov · PHASE2 · COMPLETED · 2019-05-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2018-05-15
Indexed literature (PubMed)11
Block GA et al. · JAMA · 2017
Nakai K et al. · Ther Apher Dial · 2024
Baker DE · Hosp Pharm · 2017
PubMed · 2006
Eidman KE et al. · Semin Dial · 2018
Zhu Y et al. · Clin Nephrol · 2020
Hamano N et al. · Expert Opin Pharmacother · 2017
Bernardor J et al. · Curr Osteoporos Rep · 2023
Blair HA · Drugs · 2016
Freitas P et al. · Nefrologia (Engl Ed) · 2025
Palmer SC et al. · Am J Kidney Dis · 2020
Keep reading